secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001683168-24-004415
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic appoints Parslow Interim CEO at $400k salary, $100k retention bonus; separations with former CEO/CSO
--------------------------------------------------------------------------------

- James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.
- Parslow eligible for $100,000 cash retention bonus if employed for ten months; receives option for 20,000 shares.
- Confidential separation agreements with former CEO Jeffrey Eisenberg and former CSO Curtis Lockshin providing severance per existing agreements.
- Eisenberg Separation Agreement includes accelerated vesting of all unvested stock options as of May 16, 2024.
- Stock option grant vests 1/4 on grant date and 1/4 on each of first three anniversaries, subject to continued employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/0001683168-24-004415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824004415/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer